The pharmaceutical industry has reached an inflection point where scientific potential is outstripping traditional economic models. As pricing reforms and shifting trade policies create immediate fiscal pressure, the sector is moving away from temporary market fluctuations towards a period of permanent structural change.
This keynote explores the strategic necessity of balancing short-term commercial demands against the long-term investment required for next-generation infrastructure. As medicines are increasingly viewed as national assets, leadership must move beyond traditional efficiency to ensure the next wave of medical advancement remains viable in a fragmented global landscape
This session is available to attendees with a Leader or Networking Leader pass.
